352 related articles for article (PubMed ID: 20070504)
1. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
2. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
3. Client and staff experiences of a co-located service for hepatitis C care in opioid substitution treatment settings in New South Wales, Australia.
Treloar C; Rance J; Grebely J; Dore GJ
Drug Alcohol Depend; 2013 Dec; 133(2):529-34. PubMed ID: 23932843
[TBL] [Abstract][Full Text] [Related]
4. How to build trustworthy hepatitis C services in an opioid treatment clinic? A qualitative study of clients and health workers in a co-located setting.
Treloar C; Rance J;
Int J Drug Policy; 2014 Sep; 25(5):865-70. PubMed ID: 24559604
[TBL] [Abstract][Full Text] [Related]
5. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
6. Knowledge and barriers associated with assessment and treatment for hepatitis C virus infection among people who inject drugs.
Treloar C; Hull P; Dore GJ; Grebely J
Drug Alcohol Rev; 2012 Nov; 31(7):918-24. PubMed ID: 22612899
[TBL] [Abstract][Full Text] [Related]
7. Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study.
Alavi M; Grebely J; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S62-9. PubMed ID: 23884068
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with hepatitis C knowledge among a sample of treatment naive people who inject drugs.
Treloar C; Hull P; Bryant J; Hopwood M; Grebely J; Lavis Y
Drug Alcohol Depend; 2011 Jul; 116(1-3):52-6. PubMed ID: 21194852
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia.
Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ
Int J Drug Policy; 2015 Oct; 26(10):992-8. PubMed ID: 25697089
[TBL] [Abstract][Full Text] [Related]
10. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
11. The drugs that dare not speak their name: Injecting and other illicit drug use during treatment for hepatitis C infection.
Hopwood M; Treloar C
Int J Drug Policy; 2007 Oct; 18(5):374-80. PubMed ID: 17854725
[TBL] [Abstract][Full Text] [Related]
12. Barriers and facilitators for assessment and treatment of hepatitis C virus infection in the opioid substitution treatment setting: insights from the ETHOS study.
Treloar C; Rance J; Dore GJ; Grebely J;
J Viral Hepat; 2014 Aug; 21(8):560-7. PubMed ID: 24299222
[TBL] [Abstract][Full Text] [Related]
13. Alcohol use reduction program in methadone maintained individuals with hepatitis C virus infection.
Nyamathi A; de Castro V; McNeese-Smith D; Nyamathi K; Shoptaw S; Marfisee M; Khalilifard F; Cohen A
J Addict Dis; 2008; 27(4):27-33. PubMed ID: 19042588
[TBL] [Abstract][Full Text] [Related]
14. 'Not just methadone Tracy': transformations in service-user identity following the introduction of hepatitis C treatment into Australian opiate substitution settings.
Rance J; Treloar C;
Addiction; 2014 Mar; 109(3):452-9. PubMed ID: 24678545
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C testing and status among opioid substitution treatment clients in New South Wales.
Shand FL; Day C; Rawlinson W; Degenhardt L; Martin NG; Nelson EC
Aust N Z J Public Health; 2014 Apr; 38(2):160-4. PubMed ID: 24690055
[TBL] [Abstract][Full Text] [Related]
16. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration.
Swan D; Long J; Carr O; Flanagan J; Irish H; Keating S; Keaveney M; Lambert J; McCormick PA; McKiernan S; Moloney J; Perry N; Cullen W
AIDS Patient Care STDS; 2010 Dec; 24(12):753-62. PubMed ID: 21138381
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
Midgard H; Bramness JG; Skurtveit S; Haukeland JW; Dalgard O
PLoS One; 2016; 11(11):e0166451. PubMed ID: 27846264
[TBL] [Abstract][Full Text] [Related]
18. Factors influencing pharmacy services in opioid substitution treatment.
Chaar BB; Wang H; Day CA; Hanrahan JR; Winstock AR; Fois R
Drug Alcohol Rev; 2013 Jul; 32(4):426-34. PubMed ID: 23442133
[TBL] [Abstract][Full Text] [Related]
19. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
[TBL] [Abstract][Full Text] [Related]
20. Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy.
Jerkeman A; Norkrans G; Lidman C; Westin J; Lagging M; Frimand J; Simonsberg C; Kakko J; Widell A; Björkman P
Eur J Gastroenterol Hepatol; 2014 May; 26(5):523-31. PubMed ID: 24637496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
